Cytomegalovirus-specific T-cell therapy - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center

Drug Profile

Cytomegalovirus-specific T-cell therapy - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center

Alternative Names: ATA-230; CMV targeted T-cell therapy - Atara/MSKCC; CMV-CTL - Atara/MSKCC; CMV-peptide-specific T-cells - Atara/MSKCC; CMV-pp65 CTL - Atara/MSKCC; CMVpp65-specific T-cells - Atara/MSKCC; Cytomegalovirus virus specific cytotoxic T-lymphocytes - Atara/MSKCC; Cytomegalovirus-pp65-specific-cytotoxic-T-lymphocytes-Atara/MSKCC

Latest Information Update: 18 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Class Antivirals; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cytomegalovirus infections

Most Recent Events

  • 11 Dec 2017 Updated adverse events and efficacy data from a phase II trial in Cytomegalovirus infections treatment released by Atara Biotherapeutics
  • 01 Nov 2017 Interim adverse events and efficacy data from a phase II trial in Cytomegalovirus infections treatment released by Atara Biotherapeutics
  • 26 Oct 2017 Atara Biotherapeutics receives Rare Pediatric Disease designation from the US FDA for Cytomegalovirus-specific T cell therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top